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Peripheral and central 
neuroinflammatory changes  
and Pain Behaviors in an animal 
Model of Multiple sclerosis
Samuel S. Duffy, Chamini J. Perera, Preet G. S. Makker, Justin G. Lees, Pascal Carrive and 
Gila Moalem-Taylor*
School of Medical Sciences, UNSW Medicine, The University of New South Wales (UNSW Australia), Sydney, NSW, Australia
Pain is a widespread and debilitating symptom of multiple sclerosis (MS), a chronic 
inflammatory demyelinating disease of the central nervous system. Although central 
neuroinflammation and demyelination have been implicated in MS-related pain, the 
contribution of peripheral and central mechanisms during different phases of the disease 
remains unclear. In this study, we used the animal model experimental autoimmune 
encephalomyelitis (EAE) to examine both stimulus-evoked and spontaneous pain behav-
iors, and neuroinflammatory changes, over the course of chronic disease. We found 
that mechanical allodynia of the hind paw preceded the onset of clinical EAE but was 
unmeasurable at clinical peak. This mechanical hypersensitivity coincided with increased 
microglial activation confined to the dorsal horn of the spinal cord. The development of 
facial mechanical allodynia also emerged in preclinical EAE, persisted at the clinical peak, 
and corresponded with pathology of the peripheral trigeminal afferent pathway. This 
included T cell infiltration, which arose prior to overt central lesion formation and specific 
damage to myelinated neurons during the clinical peak. Measurement of spontaneous 
pain using the mouse grimace scale, a facial expression-based coding system, showed 
increased facial grimacing in mice with EAE during clinical disease. This was associated 
with multiple peripheral and central neuroinflammatory changes including a decrease 
in myelinating oligodendrocytes, increased T cell infiltration, and macrophage/microg-
lia and astrocyte activation. Overall, these findings suggest that different pathological 
mechanisms may underlie stimulus-evoked and spontaneous pain in EAE, and that 
these behaviors predominate in unique stages of the disease.
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inTrODUcTiOn
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by 
widespread focal areas of inflammation, demyelination, gliosis, and neurodegeneration. Typical 
onset is between the ages of 20 and 30, and it is the most common cause of chronic neurologi-
cal disability in early to middle adult life (1–3). Of the multitude of sensory, cognitive, and motor 
symptoms associated with the disease, pain has recently been estimated to have a lifetime prevalence 
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of 66.5% (4). It severely impacts the quality of life of sufferers and 
is particularly difficult to treat (5, 6). Pain in MS may be nocicep-
tive (arising as a result of non-neural tissue damage by activation 
of nociceptors), neuropathic (a consequence of direct damage to 
the somatosensory system), or mixed. Specific conditions include 
trigeminal neuralgia and Lhermitte’s phenomenon (neuropathic; 
due to ectopic impulse generation along primary afferents), 
ongoing extremity pain (neuropathic; secondary to lesion for-
mation in the spino–thalamo–cortical pathways), painful tonic 
spasms and spasticity pain (mixed; mediated by nociceptors and 
arises secondary to lesions in the central motor pathways), pain 
associated with optic neuritis (nociceptive; originating from 
nervi nervorum), musculoskeletal pains (nociceptive; secondary 
to motor disorders), and migraine (nociceptive; resulting from 
predisposition or secondary to midbrain lesions) (7). As it stands, 
there is a dire need for effective and targeted therapies aimed at 
the amelioration of pain in MS. This is an issue that, at least in 
part, stems from a lack of reliable and translatable pain outcome 
measures in animal models of MS.
Experimental autoimmune encephalomyelitis (EAE) is the 
most commonly used experimental animal model of MS, which 
shares many key pathological characteristics with the human dis-
ease; namely neuroinflammation, demyelination, and neuronal 
damage (8). Further, mice with EAE have been shown to develop 
pain behaviors including thermal hyperalgesia and mechanical 
and cold allodynia of the tail, hind paws, and fore paws in mild 
and preclinical EAE (9–14). An obvious limitation of these 
approaches arises from the confounding tail and hind limb 
motor impairment characteristic of clinical EAE, which impedes 
the testing of pain behaviors due to absent withdrawal reflexes 
during periods of paralysis. A recent study demonstrated that 
mice with EAE develop increased sensitivity to air puffs applied 
to the whisker pad indicating altered facial sensitivity in EAE 
(15). Although unclear, it is widely believed that stimulus-evoked 
pain behaviors in EAE occur as a result of inflammation, glial 
activation, and demyelination in areas involved in the process-
ing of painful stimuli such as the dorsal horn of the spinal cord 
(SC) (10) and trigeminal afferent pathways (15). Most recently, 
the early emergence of neuropathic pain-like behaviors in the 
sequelae of EAE has been investigated and was shown to be 
associated with altered excitatory–inhibitory balance within the 
primary somatosensory cortex (16) and increased expression 
of the neuronal injury marker activating transcription factor-3 
(ATF-3) in sensory neurons of the peripheral ganglia (17), both 
of which arose prior to an overt adaptive immune response and 
motor symptoms.
The study of pain in EAE has so far been focused on measures 
of hyperesthesia, which while nonetheless useful, may prove 
problematic when attempting to translate analgesic therapies 
optimized in mice to the treatment of spontaneous forms of 
neuropathic pain in MS patients. We hypothesized that mice with 
EAE develop spontaneous pain in addition to stimulus-evoked 
pain and aimed to examine such pain behaviors in association 
with neuroinflammatory changes over the course of chronic EAE. 
We show, for the first time, that in addition to stimulus-evoked 
pain (facial allodynia measured by whisker pad sensitivity to 
mechanical stimuli) mice with EAE also develop spontaneous 
pain (facial grimacing measured by the mouse grimace scale, 
a facial expression-based pain coding system), an important 
component of MS-associated pain. Comprehensive analysis 
of immune, glial, and neural changes in correspondence with 
observable pain behaviors shows that distinct stages of EAE are 
associated with specific pain phenotypes and neuroinflammation 
in both the peripheral and CNS.
MaTerials anD MeThODs
animals
Female C57BL/6J mice aged 10–12 weeks (Australian Biological 
Resources, Moss Vale, NSW, Australia) were used in all experi-
ments. Mice were housed in individually ventilated cages with 
water and food ad libitum in groups of 3–5 and maintained on 
a 12-h light–dark cycle. The facility was kept at a constant room 
temperature (RT) and humidity, and the animals were monitored 
daily throughout experiments. All experiments were approved by 
the Animal Care and Ethics Committee of the University of New 
South Wales, Sydney, NSW, Australia.
eae induction and assessment
Experimental autoimmune encephalomyelitis was induced 
by subcutaneous immunization with myelin oligodendrocyte 
glycoprotein 35–55 (MOG35–55) emulsified in complete Freund’s 
adjuvant (CFA). Emulsions were purchased from Hooke 
Laboratories (Lawrence, MA, USA) as prefilled syringes, each 
containing ~1 mg/mL MOG35–55 emulsified with 2–5 mg killed 
Mycobacterium tuberculosis H37Ra/mL in incomplete Freund’s 
adjuvant. Control mice were immunized with CFA alone (Hooke 
Laboratories; at the same concentration given to mice immunized 
with MOG35–55/CFA). Immunizations were given under 3–5% 
isoflurane anesthesia in oxygen as 2  ×  100  μL subcutaneous 
injections; one at the base of the tail and one on the upper back. 
An intraperitoneal injection of 200  ng Pertussis Toxin (Hooke 
Laboratories) in 100  μL Dulbecco’s Phosphate Buffered Saline 
(D-PBS; Life Technologies Pty Ltd., VIC, Australia) was given 
to all mice 2–6  h after subcutaneous immunization, and again 
22–26 h later.
Post-induction, mice were monitored daily for body weight 
and EAE clinical scores according to a detailed EAE grading sys-
tem supplied by Hooke Laboratories. Briefly, EAE clinical scores 
were assigned as follows: Grade 1 =  limp tail; Grade 2 =  limp 
tail and weakness of hind legs; Grade 3 = limp tail and complete 
paralysis of hind legs or limp tail with paralysis of one front and 
one hind leg; Grade 4 =  limp tail and complete hind leg and 
partial front leg paralysis; Grade 5 = complete hind and complete 
front leg paralysis.
Measurement of hind Paw  
Mechanical allodynia
Hind paw mechanical allodynia was assessed by placing mice 
in 10 ×  10  cm red-tinted chambers on an elevated wire mesh. 
Mice were habituated to the behavioral testing apparatus twice 
for 1  h each prior to baseline testing. Mechanical allodynia of 
the hind paws was assessed using a set of calibrated von Frey 
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filaments. These were applied to the mid-plantar surface of the 
hind paw until bending and maintained for 3 s. Paw withdrawals 
were noted as swift, sharp responses to application of the fila-
ment, and testing was conducted blind to experimental groups 
using Dixon’s up-and-down method (18). A 50% paw withdrawal 
threshold (PWT) per animal was found by averaging the 50% 
PWT calculated for each paw.
Measurement of Facial  
Mechanical allodynia
Facial allodynia was assessed using a method previously described 
by Lyons et al. to measure facial pain in a model of trigeminal 
inflammatory compression injury (19). In the week prior to 
baseline behavioral testing, animals were handled daily using a 
cotton glove in order to gradually acclimatize the mice to being 
gently restrained in the experimenter’s hand. Prior to testing, the 
same experimenter gently restrained the mouse in their palm 
with the head exposed using the cotton glove until the mouse 
was acclimated and calm. During testing, a second experimenter 
blinded to experimental groups applied a 0.07  g von Frey fila-
ment to the whisker pad five times per side, with a 1-min interval 
between tests. Responses were recorded as head withdrawal, fore 
paw swiping, or facial flinching by a blinded experimenter, and 
a percentage of total responses over the five tests per side were 
calculated for each animal.
Mouse grimace scale
Mice were habituated for 15 min once prior to baseline testing in a 
5 × 5 × 10 cm plastic arch with glass windows at each end placed 
on an elevated wire mesh. During testing, mice were placed in the 
same arch, with two Canon 500D cameras positioned at each end 
for high definition video recording. Mice were filmed for 11 min 
total, and screen grabs were later taken at each minute mark fol-
lowing beginning of recording for a total of 10 photos per mouse. 
These were taken as soon as a clear head shot could be observed 
and scored according to the criteria developed by Langford and 
colleagues (20) with the omission of the whisker change action 
unit as this was deemed difficult in C57BL/6J mice due to coat 
color (Figure 2A). Mean mouse grimace scale (MGS) difference 
scores from baseline were calculated in a blinded manner at time 
points tested post-EAE induction.
Flow cytometry
At designated end-points post-EAE induction (day 8 pre-onset, 
day 16 clinical peak, and day 32 chronic phase), mice were 
euthanized using 0.1 mL of Lethabarb (Virbac, NSW, Australia), 
injected i.p. and were transcardially perfused with heparinised 
0.9% saline solution. The L3–5 dorsal root ganglia (DRG; left 
and right), SC, brain, and trigeminal tissue (nerve and ganglia; 
right) were then dissected and placed into PBS on ice. Tissues 
were coarsely chopped and incubated with 1  mL of Accutase 
(Sigma Aldrich, NSW, Australia) for 30  min at 37°C and 5% 
CO2. Tissues were then mechanically ground through 70 μm cell 
strainers (BD Biosciences, Franklins Lakes, NJ, USA) in 10 mL 
of PBS. Cell suspensions were centrifuged for 5 min at 1000 × g 
at 4°C, before discarding the supernatant. 10 mL of 30% Percoll 
(GE Healthcare Australia Pty Ltd., NSW, Australia) in PBS was 
added to each sample, which were then centrifuged for 25 min at 
600 × g at RT. The supernatant, including the myelin/cell debris 
layer, was carefully removed using a pipette, and the cell pellet 
was resuspended in 1  mL of autoMACS (magnetic-activated 
cell sorting; Miltenyi Biotec Australia Pty Ltd., NSW, Australia) 
running buffer. Samples were centrifuged for 5 min at 600 × g at 
4°C, before removing as much of the supernatant from the pellet 
as possible using a pipette. Cells were counted and PBS added to 
give a final cell concentration of ~1 × 107 cells per mL.
One hundred microliters of cells from each sample were 
divided into separate tubes, and 1  μL of Zombie Violet cell 
viability dye (Biolegend, CA, USA) was added to each tube, which 
were incubated in the dark for 15 min at RT. Cells were washed 
once in 1 mL of autoMACS running buffer by centrifuging for 
5 min at 600 × g at 4°C, the supernatant was discarded and the 
residual volume was incubated with 1  μL anti-mouse CD16/
CD32 Fc Block (eBioscience, CA, USA) for 5  min at RT. For 
analysis of premyelinating and myelinating oligodendrocytes, 
primary anti-galactocerebroside (GALC) and anti-MOG anti-
bodies (Merck Millipore, VIC, Australia) were first conjugated 
to unique fluorophores using Lightning-Link Antibody Labeling 
kits (Novus Biologicals, Littleton, CO, USA) as per manufacturer’s 
instructions. Anti-GALC-PE and anti-MOG-FITC conjugated 
antibodies were then incorporated into a standard flow cytom-
etry staining protocol as follows. Antibodies including anti-
CD45-APC (eBioscience; 1:1000), anti-CD4-FITC (eBioscience; 
1:1000), Anti-GALC-PE (1:200), and anti-MOG-FITC (1:200) 
diluted in 100 μL of autoMACS running buffer were added to 
each sample, and cells were incubated for 30 min at 4°C in the 
dark. Appropriate isotype and fluorescence minus one controls 
were included by staining 100  μL of pooled samples for each 
tissue analyzed. After staining, cells were washed three times in 
1 mL of autoMACS running buffer before being resuspended in 
0.2 mL of the same buffer for analysis on a BD FACS Canto II 
flow cytometer. A minimum of 50,000 events was acquired per 
sample, and data were analyzed using FlowJo software (FlowJo, 
OR, USA).
immunohistochemistry
At designated end-points post-EAE induction (day 8 pre-onset 
and day 16 clinical peak), mice were euthanized and transcardi-
ally perfused with heparinised 0.09% saline solution followed by 
10% formalin solution (Sigma Aldrich). The L3–5 DRG, L3–5 
SC, brain (including brain stem), and trigeminal tissue was then 
dissected and post-fixed in formalin solution overnight at 4°C. 
The medulla was then dissected from the brain, and all tissues 
were transferred to 30% sucrose + 0.1% sodium azide solution 
and stored at 4°C until sectioning. Sections were cut using a 
cryostat (Leica Biosystems, Buffalo grove, IL, USA), with DRGs, 
and trigeminal tissue samples sectioned longitudinally at a thick-
ness of 10 μm, and SC and medulla samples sectioned coronally 
at a thickness of 20 μm. All sections were cut sequentially such 
that each slide contained 4–6 serial sections representative of the 
entire thickness of the tissue. Sections were transferred directly 
to gelatin-coated glass slides, air dried overnight, and stored 
at −80oC until staining.
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Prior to staining, sections were fixed with ethanol for 10 min at 
RT. Sections were then washed twice with distilled water and once 
with PBS containing 0.05% Tween-20 (PBS-T). A blocking solu-
tion containing PBS with 5% donkey or goat serum, 0.2% Tween-
20, and 0.3% Triton X-100 was applied to each slide for incubation 
at RT for 1 h in the dark. The blocking solution was drained, and 
sections were incubated with the following antibodies diluted in 
PBS containing 5% bovine serum albumin and 0.03% Triton-X: 
rat anti-mouse CD3 (T cells; 1:100; R&D systems, MN, USA), 
rabbit anti-mouse/rat IBA-1 (ionized calcium-binding adap-
tor-1; macrophages/microglia; 1:2000; Wako Chemicals USA, 
Richmond, VA, USA), mouse anti-mouse GFAP (glial fibrillary 
acidic protein; activated astrocytes; 1:2000; Chemicon, Temecula, 
CA, USA), rabbit anti-mouse ATF-3 (activating transcription 
factor-3; cell damage; 1:400; Santa Cruz Biotechnology Inc., TX, 
USA), goat anti-mouse CGRP (calcitonin gene-related peptide; 
peptidergic neurons; 1:1000; Abcam, VIC, Australia), anti-mouse 
IB4-FITC (isolectin B4; non-peptidergic neurons; 1:100; Sigma 
Aldrich), and rabbit anti-mouse NF200 (neurofilament 200; 
myelinated neurons; 1:1000; Sigma Aldrich). IBA-1 and GFAP 
primary antibody incubation was conducted at RT for 1 h, while 
all other primary antibodies were incubated overnight at 4°C. 
Sections were then washed four times with PBS-T for 10 min each, 
before adding secondary antibodies, which included: Alexa Fluor 
488 conjugated donkey anti-mouse (1:1000; Life Technologies, 
Mulgrave, VIC, Australia), Alexa Fluor 546 conjugated donkey 
anti-rabbit (1:1000; Life Technologies), or Cy3 conjugated don-
key anti-rabbit (1:1000; Jackson ImmunoResearch Laboratories 
Inc., PA, USA) in the same buffer as the primary antibody. 
Negative staining controls were incorporated whereby tissues 
were incubated with secondary antibody alone in the absence 
of the relevant primary antibody (to control for non-specific 
binding of the secondary antibody). Following a 1 h incubation 
at RT in the dark, sections were washed four times in PBS-T for 
10 min each. Prolong gold anti-fade reagent with 4′, 6-diamidino-
2-phenylindole (DAPI; Life Technologies) was applied before 
slides were cover slipped and stored at 4°C until viewing.
image analysis
Analysis of images was conducted blind to experimental groups 
from which the tissue was derived.
Trigeminal Ganglia and Dorsal Root Ganglia
For each animal, slides containing 4–6 sections of the L3–5 
DRGs (left and right, with two of each L3–5 DRG represented in 
each section) or trigeminal tissue (left) were stained for a given 
antibody. For DRGs, images were taken of 2–3 DRGs contained 
in each section (a total of 12–18 images per slide/animal). In 
trigeminal ganglia (TG), images of areas containing cell bodies 
(inclusive of the ophthalmic, maxillary, and mandibular distri-
butions of ganglia) were taken at 20× magnification for each 
section (a total of 12–18 images per slide/animal). Using Image 
J software, immunoreactive cells were either manually counted 
and expressed per area of ganglion (CD3 analyzes), counted and 
expressed as a percentage of total cell bodies in the ganglia of 
interest (ATF-3 and neuropeptide analyses), or expressed as a 
percentage of immunoreactivity after subtracting background 
(IBA-1 analyses). Values for each image of ganglia regions were 
averaged to give a mean immunoreactivity per animal.
Trigeminal Nerve and Trigeminal Root Entry Zone
Slides containing 4–6 sections of left trigeminal tissue per 
animal were stained for a given antibody. Images were taken at 
20× magnification of regions immediately distal to the CNS-
peripheral nervous system (PNS) junction (trigeminal nerve; 
TN images) and just proximal to the CNS–PNS junction at 
the trigeminal root entry zone (TREZ) (4–6 images per slide/
animal). Immunoreactive cells were either manually counted 
and expressed per area of nerve (CD3 analyses) or expressed as 
a percentage of immunoreactivity after subtracting background 
(IBA-1 analyses) using Image J software. Values for each section 
were averaged to give the mean immunoreactivity per animal.
Spinal Cord and Spinal Trigeminal Nucleus
Slides containing 4–6 sections of L3–5 SC or medulla per animal 
were stained for a given antibody. For SC sections, images were 
taken at 20× magnification of the left and right ventral and dorsal 
horn regions (8–12 images of ventral horn, and 8–12 images of 
dorsal horn regions per animal/slide). Sections of the medulla 
were taken around the level of the obex in the caudal medulla 
in order to visualize the region corresponding to the spinal 
trigeminal nucleus (STN) (sections were inclusive of the subnu-
cleus caudalis, subnucleus interpolaris, and subnucleus oralis). 
Images were taken at 20× magnification in regions of the left and 
right STN (8–12 images per animal/slide). Image J software was 
used to calculate the percentage of total immunoreactivity after 
subtracting background. Values for each region were averaged 
across sections to give the mean immunoreactivity per animal.
Image Acquisition
All images were viewed using Olympus BX51 epifluorescence 
microscope, and images captured using an Olympus DP73 camera 
using cellSens software (Olympus, Tokyo, Japan). All images for a 
particular stain were taken using identical microscope settings.
statistical analysis
All statistical analyses were conducted using GraphPad Prism 6 
software. Since pain behavioral data sets involving the testing of 
mechanical allodynia proved to be not normally distributed using 
a Shapiro–Wilk normality test, a non-parametric Mann–Whitney 
test was used as the most appropriate statistical test for comparing 
two groups – EAE mice vs. control mice at each time point. The 
Holm–Bonferroni correction for multiple comparisons was then 
used to account for multiple testing. MGS data were analyzed 
using a repeated measures two-way ANOVA (treatment; time) 
with Tukey’s post  hoc test. Immunohistochemistry data were 
analyzed using an unpaired student’s t-test (when comparing two 
groups; EAE mice vs. control mice) or a one-way ANOVA with 
Tukey’s post hoc test (when comparing greater than two groups in 
neuropeptide analyses) at individual time points. Multiple time 
point flow cytometry data were analyzed using two-way ANOVA 
(treatment; time) with Tukey’s post hoc test. Pain behavioral data 
sets analyzed using non-parametric statistical tests (hind paw and 
facial allodynia) are presented as box and whisker plots, where 
FigUre 1 | eae disease progression and evoked pain behaviors observed over the course of chronic eae. Disease progression of EAE (a) and (B) body 
weight over the 32-day monitoring period post-induction in control and EAE mice (n = 20). Time points chosen for analysis of nervous tissue at preclinical, peak, 
and chronic phases of disease are indicated in (a). (c) Mechanical allodynia of the hind paw observed in the preclinical period in mice with EAE. At days 8 and 10 
post-induction, EAE mice showed significantly reduced 50% paw withdrawal thresholds (PWTs) compared to control mice (n = 6–15). (D) Facial allodynia observed 
in mice over the course of chronic EAE. At days 6, 8, 10, 17 and 30 post-induction, EAE mice recorded a significantly increased percentage of responses to the 
mechanical stimulus applied to the whisker pad compared to control mice (n = 4–9).  *P < 0.05, **P < 0.01, and ***P < 0.001, Mann–Whitney test with Holm–
Bonferroni correction for multiple comparisons. EAE clinical scores and body weight data are expressed as mean ± SEM, while pain behavioral data are expressed 
as box and whisker plots where box limits show the first and third quartile, the center line is the median, and the whiskers represent the minimum and maximum 
values.
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box limits show the first and third quartile, the center line is the 
median and the whiskers represent the minimum and maximum 
values. MGS, flow cytometry, and immunohistochemistry data 
are presented as arithmetic mean ± SEM. The level of significance 
was set as p < 0.05 for all analyses.
resUlTs
increased stimulus-evoked Pain and 
Facial grimacing in Mice with eae
To investigate pain symptoms during the course of chronic EAE, 
mice were immunized with the MOG35–55 peptide in CFA. Mice 
developed chronic EAE with typical disease onset between 10 and 
13 days post-induction, a mean peak clinical score of 3 on day 
16, and a gradual, partial recovery to a mean clinical score of 2 
by day 32 post-induction. Control mice immunized with CFA 
alone did not develop any clinical signs of EAE over the 32-day 
monitoring period (Figure 1A). Clinical EAE was accompanied 
by a significant loss of body weight, which was most severe at 
time points corresponding to the EAE clinical peak (Figure 1B).
To assess stimulus-evoked pain, we first tested mechanical 
pain hypersensitivity in the hind paws (Figure 1C). Compared 
to controls, EAE mice showed reduced 50% PWTs during the 
pre-clinical stage of disease on days 8 and 10 post-induction 
(n =  6–15, p <  0.01). Corresponding to the onset of clinical 
EAE and accompanying hind limb motor impairment, the 50% 
PWTs of EAE mice showed a sharp rise on day 15 (clinical peak 
FigUre 2 | Facial grimacing observed over the course of chronic eae. (a) Representative images of action units analyzed as part of the mouse grimace 
scale (MGS) scoring. Control images depict an MGS score of 0 for each of the given action units, while white arrows indicate action units which scored 1–2 on the 
MGS in EAE mice. (B) Mean MGS difference scores calculated from control and EAE mice over the course of chronic EAE. Significant increases in MGS scores 
were seen at days 16 and 30 in EAE mice compared to control mice (n = 7–8). **P < 0.01 and ****P < 0.0001, repeated measures two-way ANOVA followed by 
Tukey’s post hoc test. Data are expressed as mean ± SEM.
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of disease) where PWTs rose above baseline levels and reached 
the imposed upper limit of von Frey testing in all animals (1.4 g; 
Figure  1C). Testing of mechanical pain hypersensitivity in the 
hind paws was terminated at disease peak due to paralysis. The 
restrictions imposed by hind limb motor confounds on continual 
testing of mechanical allodynia in clinical EAE prompted us to 
use a technique developed for testing mechanical pain in the 
face (19), which is not affected by motor deficits. We found that 
EAE mice were significantly more responsive to mechanical 
stimuli applied to the whisker pad than control mice over the 
entire course of chronic EAE, as seen on days 6, 8, 10, 17, and 30 
(Figure 1D, n = 4–9, p < 0.05–0.001).
To assess spontaneous (as opposed to experimenter-evoked) 
pain in EAE, we utilized the MGS (Figure 2A), a standardized 
murine facial expression-based coding system (20). This allowed 
both continuous testing of pain behaviors during paralytic clinical 
disease, and the assessment of spontaneous pain in EAE, which 
has not yet been explored in the model. No change in mean MGS 
scores were seen in the preclinical period (day 8); however, the 
mean MGS scores in EAE mice were higher at day 16 (n = 7–8, 
p < 0.01) and day 30 (n = 7–8, p < 0.01) post-EAE induction as 
compared to control mice (Figure 2B).
changes in the Proportions of 
Premyelinating and Myelinating 
Oligodendrocytes in the cns of Mice  
with eae
Given the fact that oligodendrocyte damage in the absence of 
an innate or adaptive immune response is sufficient to confer 
central pain behaviors in mice (21), we next investigated 
whether oligodendrocyte changes are associated with the pain 
FigUre 3 | The proportion of premyelinating to myelinating oligodendrocytes over the course of chronic eae. Flow cytometry to identify proportions of 
GALC + MOGlow premyelinating to GALC + MOGhigh myelinating oligodendrocytes in the brain and spinal cord (SC) was carried out in EAE and control mice. 
Mononuclear cells were first gated (a), followed by consecutive gating of singlets (B), live cells (c), and CD45lowGALC+ cells for further analysis (D). Representative 
histograms showing numbers of MOGhigh cells and MOGlow cells in control mice (e) and EAE mice (F). Bar graphs showing significant decreases in MOGhigh 
myelinating, and subsequent significant increases in MOGlow premyelinating, oligodendrocytes in the brain (g), and SC (h) of EAE mice compared to control mice at 
day 16 and 32 post-induction. No difference was seen between experimental groups preclinically at day 8. In the SC (h), a significant decrease in MOGhigh 
myelinating and subsequent significant increase in MOGlow premyelinating oligodendrocytes was also observed in EAE mice at day 32 compared to EAE mice at day 
16. *P < 0.05, **P < 0.01, and ****P < 0.0001, two-way ANOVA followed by Tukey’s post hoc test, n = 3–5. Data are expressed as mean ± SEM.
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behaviors observed in our chronic EAE model. Flow cytometry 
was used to quantify changes in CNS myelination, as previously 
described (22). CD45lowGALC  +  MOGlow premyelinating and 
CD45lowGALC + MOGhigh myelinating oligodendrocyte popula-
tions in the brain and SC were assessed over the course of chronic 
EAE. Mononuclear cells were first gated, followed by selection of 
live singlets (Figures 3A–C). CD45low resident CNS cells positive 
for GALC were then gated (Figure 3D) and analyzed for changes 
in MOG positivity between control (Figure 3E) and EAE mice 
(Figure 3F).
No changes in myelination were found in the brain or SC 
at the preclinical stage of EAE (day 8 post-EAE induction, 
n =  5). At the clinical peak (day 16 post-induction), decreases 
in GALC+ MOGhigh oligodendrocytes were seen, accompanied 
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by a subsequent increase (n = 5, p < 0.0001) in the proportion 
of GALC+ MOGlow premyelinating oligodendrocytes in the 
brain (Figure 3G) and SC (Figure 3H). This was also apparent 
in the chronic phase of EAE (day 32 post-induction) in the 
brain (Figure 3G, n = 3, p < 0.01) and SC (Figure 3H, n = 3, 
p <  0.0001). Interestingly, despite the partial recovery typical 
of mice entering the chronic phase of EAE, this regain of hind 
limb movement was associated with progressive and continued 
loss of GALC+ MOGhigh myelinating oligodendrocytes in the SC 
(Figure 3H, n = 3, p < 0.05).
The lack of a difference in oligodendrocyte subtypes in the pre-
clinical stage suggests that CNS demyelination has not yet taken 
place at day 8 and does not correspond with the early emergence 
of allodynia in the sequelae of our EAE model.
Peripheral and central changes in cD4+ 
cell infiltration in Mice with eae
To investigate changes in neuroinflammation, we first assessed 
infiltration of cells expressing CD4 (a marker expressed predomi-
nantly on the surface of helper T cells as well as minor populations 
of other immune cells) into the CNS and peripheral ganglia over 
the course of chronic EAE using flow cytometry. Mononuclear 
cells were gated (as in Figure 3A) and single cells selected (as in 
Figure 3B), before gating viable cells (as in Figure 3C) for inclu-
sion in further analysis for CD4 positivity in control and EAE 
mice (Figures 4A,B, respectively). Results showed that CD4+ cell 
infiltration was not apparent in the preclinical period, yet was 
clearly seen at the EAE clinical peak in all tissues analyzed includ-
ing the brain, SC, trigeminal tissue, and DRG (Figures  4C–F, 
n = 4–6). CD4+ cells were also increased in the brain and SC in 
the chronic phase of the disease in EAE mice compared to control 
animals (Figures  4C,D, n =  6). A trend for increased CD4+ 
cells was seen in the trigeminal tissue of EAE mice compared 
to control animals in the chronic phase of disease, although this 
failed to reach significance (Figure 4E, n = 6, p = 0.0559). In the 
brain and DRG, CD4+ cells were reduced in the chronic phase 
compared to the EAE clinical peak (Figures 4C,F, n = 5–6). The 
absence of significant CD4+ cell infiltration at day 8 suggests that 
the preclinical allodynia observed in EAE mice is unlikely to arise 
from a central adaptive immune response.
Peripheral and central changes in 
Macrophage and glial activation and  
T cell infiltration in Preclinical eae
To determine whether an early response mediated by immune 
activation is associated with the preclinical allodynia observed 
in the hind paw and whisker pad, immunostaining for IBA-1 
(macrophage/microglia marker) and GFAP (astrocyte marker) 
was carried out. Areas analyzed for IBA-1 included the dorsal 
(DHSC) and ventral (VHSC) horns of the L3–5 SC (Figure 5A), 
STN (Figure  5B), TG, TN, and TREZ (Figure  5C). There was 
no difference between EAE and control mice in  IBA-1+ immu-
noreactivity in any of the tissue regions analyzed, except for an 
increase in IBA-1 expressing cells in the dorsal horn of the SC of 
EAE mice compared to control mice (Figures 5D,E,H, n = 4–5, 
p < 0.05). Analysis of GFAP expression in the dorsal and ventral 
horns of the SC revealed no differences in astrocyte activation 
between EAE and control mice (Figure 5I, n = 4–5).
Since flow cytometric analysis of the CNS and peripheral 
ganglia showed no increase in CD4+ cells at day 8 (Figure 4), 
immunostaining for CD3+ T cells was carried out with a focus on 
specific regions of the trigeminal afferent pathway (Figure 5C). 
This was done to ascertain whether the preclinical facial allodynia 
of EAE mice may be linked to a subtle early T cell infiltration 
into the peripheral trigeminal afferent pathway occurring prior 
to more overt central infiltration. A small but significant increase 
in CD3+ cells was found restricted to the TN (Figures 5F,G,J, 
n = 4–5, p < 0.01), and a similar trend, though not statistically 
significant, was seen in the TG (Figure 5J, n = 4–5).
Peripheral and central changes in 
Macrophage and glial activation and  
T cell infiltration in clinical eae
Immunohistochemical analysis to characterize changes in activa-
tion of macrophages/microglia in the SC and trigeminal afferent 
pathway and astrocytes in the SC at the clinical peak of EAE was 
also conducted. A substantial increase (n = 4–5, p < 0.0001) in 
IBA-1 expressing cells in both the ventral (Figures 6A,B,Q) and 
dorsal horns (Figures 6C,D,Q) of the SC in EAE mice compared to 
control mice was found. An increase in IBA-1 immunoreactivity 
was also apparent in the TN (Figures 6E,F,Q, n = 4–5, p < 0.05) 
and TREZ (Figures 6G,H,Q, n = 4–5, p < 0.05). GFAP+ cells 
were similarly increased in the ventral (Figures 6I,J,R, n = 4–5, 
p < 0.001) and dorsal (Figures 6K,L,R, n = 4–5, p < 0.001) horns 
of the SC in EAE mice compared to control mice.
Since T cell infiltration into the CNS at the EAE clinical peak 
has been demonstrated by numerous studies and by our flow 
cytometric analysis (Figure  4), we carried out immunohisto-
chemistry for CD3 in the trigeminal afferent pathway and L3–5 
DRGs. We found CD3+ cells in increased numbers within the TG 
(Figures 6M,N,S, n = 4–5, p < 0.05) and TREZ (Figures 6O,P,S, 
n =  4–5, p <  0.001) in EAE mice compared to control mice. 
A trend for increased CD3+ cells in the TN was also found, 
although this failed to reach significance (Figure 6S, n = 4–5). 
Immunostaining for CD3+ cells in the DRG showed no signifi-
cant difference in T cell numbers between EAE and control mice 
(Figure 6S, n = 4–5).
As significant changes in T cell infiltration were observed 
in the TG in clinical EAE (day 16), we next examined whether 
ATF-3 (a marker of neurons with damaged primary afferents) is 
induced in peptidergic (CGRP+) and non-peptidergic (IB4+) 
small diameter neurons, and NF200+ large diameter myelinated 
neurons using immunohistochemistry. This was of interest as 
injured DRG neurons have been linked to pain behaviors in mice 
with peripheral nerve injury (23) and rats with brachial plexus 
avulsion (24). We found a small, though significant, increase in 
the percentage of total ATF-3 immunopositive cell bodies in the 
TG of EAE (1% ± 0.2) compared to control (0.1% ± 0.05) mice 
(Unpaired Student’s t-test, n = 4–5, p < 0.01). Further analysis 
revealed ATF3+ neurons present in EAE mice (Figure  7B), 
but not controls (Figure  7A), predominantly co-expressed 
NF200. An increase in NF200+ATF-3+ cell bodies compared 
FigUre 4 | cD4+ immune cell infiltration over the course of chronic eae. Flow cytometry to identify infiltrating CD4+ cells in the brain, spinal cord (SC), 
trigeminal tissue, and dorsal root ganglia (DRG) was carried out in EAE and control mice. Mononuclear cells were first gated, followed by singlets and live cells (as in 
Figures 3a–c). Representative contour plots from trigeminal tissue showing an absence of CD4+ cells in control animals (a) and the presence of CD4+ cells in 
EAE mice (B). The percentage of CD4+ cells was significantly increased in the brain (c) and SC (D) of EAE mice compared to control mice at days 16 and 32 
post-induction. The percentage of CD4+ cells was significantly reduced in the brain (c) of EAE mice at day 32 compared to EAE mice at day 16. The percentage of 
CD4+ cells was significantly increased in the trigeminal tissue (e) and in the DRG (F) of EAE mice compared to control mice at day 16 post-induction. In the DRG 
(F), the percentage of CD4+ cells was significantly reduced in EAE mice at day 32 post-induction compared to EAE mice at day 16 post-induction. *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001, two-way ANOVA followed by Tukey’s post hoc test, n = 4–6. Data are expressed as mean ± SEM.
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FigUre 5 | Macrophage and glial activation and T cell infiltration in preclinical eae.  
 (Continued)
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IBA-1 and GFAP immunohistochemistry in the L3–5 spinal cord (SC), and IBA-1 and CD3 immunohistochemistry in the trigeminal afferent pathway were carried out 
on day 8 (preclinical EAE) in EAE and control mice. (a) Representative image of a section of L3–5 SC depicting areas of the ventral horn (VHSC) and dorsal horn 
(DHSC) selected for analysis. Scale bar equals 500 μm. (B) Representative image of a section of medulla showing the region corresponding to the spinal trigeminal 
nucleus (STN). Scale bar equals 1 mm. (c) Representative image depicting the peripheral trigeminal afferent pathway, inclusive of the trigeminal ganglia (TG), 
proximal trigeminal nerve (TN), and trigeminal root entry zone (TREZ). Scale bar equals 1 mm. Representative image of the DHSC taken from a control mouse  
(D) showing observably less IBA-1 staining than an EAE mouse (e). Scale bar equals 50 μm. Representative image of a region of TN taken from a control mouse  
(F) showing an absence of CD3+ cells, which were present in EAE mice (g). Scale bar equals 25 μm and white arrow indicates a CD3 immunoreactive cell with 
DAPI nuclear staining. (h) Bar graph summarizing levels of IBA-1 immunostaining, which were significantly increased in the DHSC of EAE mice; however, no 
difference was seen in any of the other tissues analyzed. (i) Bar graph depicting levels of GFAP immunostaining in the VHSC and DHSC, where no significant 
difference was seen between control and EAE mice. (J) Bar graph showing a significant increase in CD3+ cells in the TN, and a trend for increased numbers of 
CD3+ cells in the TG (p = 0.08). No difference was seen between experimental groups in the TREZ. *P < 0.05 and **P < 0.01, unpaired student’s t-test, n = 4–5. 
Data are expressed as mean ± SEM.
FigUre 5 | continued
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to CGRP+ATF-3+ (n =  4–5, p <  0.0001), and IB4+ATF-3+ 
(n =  4–5, p <  0.01) cell bodies was seen in the TG of mice at 
the clinical peak of EAE (Figure 7C) suggesting that neuronal 
damage is selective for myelinated NF200+ neurons.
DiscUssiOn
Although it is well established that neuroinflammation and 
demyelination are important contributors to pain behaviors in 
MS and EAE (25, 26), the relationship between the pain pheno-
types at different stages of disease and potential peripheral and 
central contributors is unclear. We found that stimulus-evoked 
and spontaneous pain in EAE may derive from unique patho-
logical mechanisms, with the former arising in the absence of 
overt central lesion formation. A subtle increase in IBA-1+ cell 
numbers was seen in the dorsal horn of the SC in preclinical 
disease, and this corresponded to increased allodynia of the hind 
paw. Analysis of the trigeminal afferent pathway revealed that 
facial allodynia coincided with peripheral changes including a 
small, but significant, infiltration of T cells into the TN during 
preclinical disease and specific damage to myelinated NF200+ 
neurons at the EAE clinical peak. Clinical EAE and the onset 
of spontaneous pain appear to be associated with more overt 
changes, with potential peripheral and central contributions.
This study was conducted in female mice to account for the 
fact that MS is universally more prevalent in women than men 
(27). We show here that female mice display both stimulus-
evoked and non-evoked pain behaviors throughout the course 
of chronic EAE, and that facial allodynia and facial grimacing 
predominate in unique stages of the disease. This finding 
suggests different underlying etiologies for EAE-induced 
evoked pain and spontaneous pain. Similarly to Thorburn and 
colleagues (15), we describe facial allodynia and trigeminal 
pathology in mice with EAE as described in patients suffering 
from trigeminal neuralgia associated with MS (28–31). In addi-
tion to effectively modeling trigeminal neuralgia, the use of von 
Frey filaments to elicit facial allodynia allows continual testing 
of cutaneous hypersensitivity during periods of otherwise 
confounding lower body motor impairment. Interestingly, the 
development of facial and hind paw allodynia arose prior to the 
onset of clinical symptoms, in line with a previous study that 
showed both mechanical and cold allodynia of the hind paw in 
the preclinical period of EAE (10). We also present the utility of 
the MGS (20) in measuring spontaneous pain over the course of 
chronic EAE, which may increase the translational capacity of 
pain research in EAE when testing analgesic therapies for MS. 
Facial palsy occurs in some patients with MS (32) and may be 
due to peripheral lesions affecting motor facial nerve fibers or 
central lesions in the area of the facial nucleus (33). While EAE is 
typically considered a central demyelinating disorder, we cannot 
exclude the possibility that increased facial grimacing may be 
influenced by demyelination of lower motor neurons resulting 
in brainstem reflex abnormalities and a compromised ability of 
EAE mice to exhibit facial expressions. Regardless, such demy-
elination is also known to be a major contributor to neuropathic 
pain (34), and therefore does not discount the interpretation of 
increased facial grimacing as a response to pain. Additionally, 
it remains unclear whether the facial grimacing observed in 
EAE mice is reflective of spontaneous pain similar to trigeminal 
neuralgia or of spontaneous pain arising in area(s) unrelated to 
the face. As the MGS was reported to be non-useful for measur-
ing neuropathic pain in peripheral nerve injury models (20), 
we cannot discount that the facial grimacing induced in EAE 
mice may be due to nociceptive pain arising as a consequence 
of musculoskeletal problems secondary to lower body paralysis 
and spasticity. Given that the majority of MS patients with 
central pain also suffer concurrent paresis (35), it is perhaps 
desirable to measure pain in stages of EAE where lower body 
motor impairment is apparent as has been made possible using 
the methods described in the current study.
A recent study demonstrated that conditional ablation of 
oligodendrocytes leads to the development of pain behaviors 
in mice. This suggests that a loss of oligodendrocyte function, 
which maintains axonal integrity in the CNS, is able to trigger 
the development of neuropathic pain (21). We therefore assessed 
demyelination over the course of chronic EAE using flow 
cytometry. Although we found decreases in GALC+ MOGhigh 
myelinating oligodendrocytes in the brain and SC in the peak 
and chronic phases of clinical EAE, no changes were observed 
in the preclinical stage. Accompanying these clinical decreases 
in myelination was a subsequent increase in GALC +  MOGlow 
premyelinating oligodendrocytes. This suggests an arrest of oligo-
dendrocyte maturation at the premyelinating stage, presumably 
due to the presence of autoreactive T cells sensitized to the MOG 
antigen. Since overt demyelination was only observed in periods 
of clinical EAE, it appears that allodynia, which predominates 
during the preclinical phase of the disease, is not directly related 
to oligodendrocyte dysfunction or damage.
FigUre 6 | Macrophage and glial activation and T cell infiltration in clinical eae.  
 (Continued)
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FigUre 7 | specific damage to myelinated a-class fibers in clinical eae. Representative images of NF200/ATF-3 double-labeling showing the presence of 
NF200+ATF-3+ cells in the trigeminal ganglion of EAE mice (B), but not control mice (a) at day 16. Scale bar equals 25 μm and white arrow indicates an NF200 
immunoreactive cell with ATF-3 nuclear staining. (c) Bar graph showing significantly increased numbers of NF200+ATF-3+ cell bodies compared to CGRP+ATF-3+ 
and IB4+ATF-3+ cell bodies in the trigeminal ganglia of EAE mice. **P < 0.01 and ****P < 0.0001, one-way ANOVA followed by Tukey’s post hoc test, n = 4–5. Data 
are expressed as mean ± SEM.
IBA-1 and GFAP immunohistochemistry in the L3–5 spinal cord (SC), IBA-1, and CD3 immunohistochemistry in the trigeminal afferent pathway and CD3 
immunohistochemistry in the L3–5 dorsal root ganglia (DRG) were carried out on day 16 (at the EAE clinical peak) in EAE and control mice. Representative images 
showing less IBA-1 immunostaining in the ventral horn of the spinal cord (VHSC) (a), dorsal horn of the spinal cord (DHSC) (c), trigeminal nerve (TN) (e), and 
trigeminal root entry zone (TREZ) (g) of control mice compared to the VHSC (B), DHSC (D), TN (F), and TREZ (h) of EAE mice. Representative images showing 
less GFAP immunostaining in the VHSC (i) and DHSC (K) of control mice compared to VHSC (J) and DHSC (l) of EAE mice. Representative images showing an 
absence of CD3+ cells in the trigeminal ganglia (TG) (M) and TREZ (O) of control mice, which were visible in TG (n) and TREZ (P) of EAE mice. Scale bar equals 
25 μm and white arrows indicate CD3 immunoreactive cells with DAPI nuclear staining. (Q) Bar graph showing significantly increased levels of IBA-1 immunostaining 
in the VHSC, DHSC, TN, and TREZ in EAE mice compared to control mice. No difference was seen in the TG between experimental groups. (r) Bar graph showing 
significantly increased levels of GFAP immunostaining in both the VHSC and DHSC in EAE mice compared to control mice. (s) Bar graph showing no difference in 
CD3+ cell numbers in the DRG, but significant increases in the TG and TREZ, as well as a trend for increased levels in the TN (p = 0.095) in EAE compared to 
control mice. *P < 0.05, ***P < 0.001, and ****P < 0.0001, unpaired student’s t-test, n = 4–5. Data are expressed as mean ± SEM.
FigUre 6 | continued
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Since previous studies have purported links between central 
lesions in areas such as the SC (9, 10, 12, 36) and trigeminal 
nuclei (15) with evoked pain behaviors, we next analyzed the 
CNS of mice with preclinical EAE for T cell infiltration and glial 
changes. No increase in CD4+ cells was observed in the brain or 
SC in the preclinical period, which suggests that a central adap-
tive immune response does not mediate allodynia in preclinical 
EAE. Glial activation in the dorsal horn of the SC and STN was 
also analyzed, and a subtle, yet statistically significant, increase 
in IBA-1-expressing cells in the dorsal horn of the SC was seen. 
Increased numbers of IBA-1+ cells have previously been shown 
in the primary somatosensory cortex in preclinical EAE (16), and 
perivascular microglial clustering in the SC occurs prior to the 
onset of clinical symptoms and demyelination. This clustering was 
shown to correlate with fibrinogen deposition in the SC, which 
was taken as a reflection of early blood–brain barrier disruption 
(37). It is unknown whether the increase in IBA-1 expressing cells 
in the dorsal horn was provoked by perivascular microglial clus-
tering in the present study, and the use of chimeric mice (38–41) 
or a marker specific for microglia (42) would allow for clarifica-
tion. Microglia have been linked to the initiation of mechanical 
allodynia in a range of chronic pain models (43–47). In particular, 
after nerve damage, spinal microglia have been shown to change 
their morphology, phenotype, and motility, express intracellular 
signaling molecules (for example, p38 mitogen-activated protein 
kinase), and release brain-derived neurotrophic factor, cytokines 
such as tumor necrosis factor (TNF) and interleukin (IL)-1β, 
and chemokines, thus potentiating aberrant nociceptive signal-
ing (48–50). It is therefore feasible that microglial activation in 
the L3–5 dorsal horn may have contributed to the mechanical 
allodynia of the hind paw seen in this study. However, a similar 
increase in IBA-1 expressing cells was not apparent in the STN 
where small diameter fibers (C and Aδ) carrying information 
concerning pain and temperature terminate. A more comprehen-
sive analysis inclusive of all brainstem trigeminal nuclei would be 
useful to elucidate whether an increase in IBA-1+ cells similar 
to what is seen in the dorsal horn of the SC is apparent in these 
areas, and whether this may play a role in the development of 
facial allodynia in preclinical EAE. It is also interesting to note 
that different immune cells have recently been shown to mediate 
neuropathic pain behavior following peripheral nerve injury 
in male and female mice. While spinal microglia mediated the 
development of mechanical pain hypersensitivity in male mice, 
T cells appeared to be responsible for such pain in female mice 
(51) suggesting sexual dimorphism in pain processing.
Given that allodynia appears to arise in the absence of distinct 
central lesion formation, we next sought to ascertain whether 
changes in the PNS are associated with stimulus-evoked pain 
in EAE. In analyzing the trigeminal afferent pathway during 
preclinical EAE (day 8), we found that facial allodynia coincided 
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with T cell infiltration into the TN. Considering we studied 
MOG35–55-induced EAE, the antigen specificity of the T cells 
infiltrating the TN, where the MOG antigen is not expressed, 
remains unknown. The clinical peak of EAE is associated with 
central neuroinflammation. T cells are known to infiltrate into 
the CNS (52) and trigeminal afferent pathway including the 
TG, TN, and TREZ (15) in EAE, and this was confirmed in the 
present study. Infiltrating CD4+ cells in EAE have previously 
been shown to be pathogenic and primarily of a Th1 and Th17 
phenotype (53, 54), both of which have been implicated in the 
generation of neuropathic pain through the production of their 
signature cytokines IFN-γ (55, 56) and IL-17 (57, 58). T cell 
infiltration along with colocalized glial activation in the superfi-
cial dorsal horn (10) and trigeminal afferent pathway (15) were 
postulated to contribute to the development of EAE-induced 
evoked hind paw and facial hypersensitivity, respectively. 
Although pain hypersensitivity developed prior to significant 
central neuroinflammation, our observation of a substantial 
infiltration of CD4+ cells in the CNS, microglia, and astrocyte 
activation in the dorsal horn of the SC, and an increased T cell 
infiltration, and macrophage/microglial activation in multiple 
areas along the trigeminal afferent pathway may have contrib-
uted to pain behaviors during EAE clinical peak. In parallel 
with another recent study (17), we found increased numbers 
of infiltrating CD4+ cells in the DRG in clinical EAE, where it 
has been previously reported that rats with EAE have elevated 
expression of fractalkine (CX3CL1) and its receptor (CX3CR1) 
(59), and increased levels of TNF-α (60, 61), and IL-1β (62). 
Innate immune cells such as NK cells, neutrophils, and mast 
cells are also known to be involved in the pathogenesis of EAE 
(63–65); however, their role in pain associated with EAE and MS 
is unclear. Mast cells in particular have been implicated in the 
production of neuropathic pain in models of peripheral nerve 
injury (66) and chemotherapy-induced peripheral neuropathy 
(67). An expanded characterization of cells such as these in the 
EAE model and their relationship to pain behaviors would be an 
important addition to the current knowledge.
The facial allodynia seen in the clinical period of EAE was 
associated with neuronal damage in myelinated A-class sensory 
fibers, but not in unmyelinated C-fibers in the TG. ATF-3 expres-
sion has also been recently shown in a mixed population of 
sensory neurons in EAE, including those with myelinated axons 
(NF200+) and in others that express TRPV1 (17). Previous studies 
in models of monoarthritic joint pain (68) and capsaicin-induced 
pain (69) have shown that damage to cell bodies in the DRG, as 
indicated by ATF-3 staining, primarily involves CGRP+ pepti-
dergic and IB4+ non-peptidergic C-fibers. EAE is a demyelinat-
ing disease, and this could account for why myelinated sensory 
fibers are injured while C-fibers appear largely preserved. Large 
myelinated Aβ fibers are implicated in the dorsal horn circuit 
responsible for producing mechanical allodynia (70, 71). Indeed, 
blockade of large diameter NF200+ A-class sensory fibers, but 
not C-fibers, abrogates mechanical allodynia in a range of neuro-
pathic pain models including chemotherapy-induced peripheral 
neuropathy, nerve injury, and diabetic neuropathy (72). Further 
studies addressing whether Aβ fibers are specifically damaged in 
EAE, and whether this occurs in the dorsal horn circuit as well 
as the trigeminal afferent pathway would help to elucidate the 
etiology of allodynia in MS.
The observation that the facial allodynia and grimacing 
observed in the current study predominate in unique clinical 
phases of EAE is an interesting one. Facial allodynia develops in 
the absence of overt central changes but rather corresponds with 
a subtle peripheral change of a small, yet significant, infiltration 
of T cells into the TN. Facial allodynia appears to quite sharply 
decrease following the onset of EAE compared to the preclinical 
period. While it is presently unknown why this occurs, hypoes-
thesia is also common in MS (35), and diminished responses 
to subcutaneous formalin injection in EAE have been linked to 
dysregulation of the glutamatergic system (73). The mechanisms 
underlying the facial grimacing observed in clinical EAE are 
likely to be multifactorial as the behavior coincides with T cell 
infiltration into the CNS, trigeminal afferent pathway and DRG, 
as well as an increase in IBA-1+ cell numbers and specific damage 
to large myelinated neurons in the trigeminal afferent pathway, 
gliosis in the dorsal horn of the SC, and central demyelination. 
Although the precise etiology of facial allodynia and grimacing 
in EAE remains unclear, both methods provide an invaluable 
approach to better understand the mechanisms involved in the 
production of pain in EAE.
In summary, we observed different pain phenotypes including 
stimulus-evoked and spontaneous pain predominating in unique 
stages of the chronic EAE model, in accordance with the diverse 
pain phenotypes seen in MS patients (6). The pain behaviors 
we observed were associated with several neuroinflammatory 
changes in both the peripheral nervous system and CNS and are 
likely to involve numerous underlying mechanisms.
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